Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Roche Holding AG | 4,639 |
| 2 | The University of Texas System | 739 |
| 3 | Gilead Sciences Inc | 496 |
| 4 | Pfizer Inc | 492 |
| 5 | Institut National de la Santé et de la Recherche Médicale | 424 |
| 6 | AbbVie Inc | 329 |
| 7 | Amgen Inc | 324 |
| 8 | Merck and Co Inc | 286 |
| 9 | AstraZeneca PLC | 282 |
| 10 | Toray Industries Inc | 265 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 19,633 |
| 2 | A61K | Medicinal preparations | 19,255 |
| 3 | C07K | Peptides | 12,996 |
| 4 | C07D | Heterocyclic compounds | 5,128 |
| 5 | C12N | Microorganisms, enzymes | 4,377 |
| 6 | G01N | Investigating / analysing materials | 3,823 |
| 7 | C12Q | Measuring/testing involving enzymes | 1,866 |
| 8 | Y02A | Climate change adaptation | 1,864 |
| 9 | C12Y | Enzyme nomenclature (EC numbers) | 786 |
| 10 | C07F | Organometallic compounds | 659 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Application of 6-diazo-5-oxo-L-norleucine in preparation of medicine for preventing and treating psoriasis | 2021 | 3 | |
| METHODS FOR BIOANALYSIS OF 6-DIAZO-5-OXO-L-NORLEUCINE (DON) AND OTHER GLUTAMINE ANTAGONISTS | 2016 | Johns Hopkins University | 2 |
| PRODRUGS OF 6-DIAZO-5-OXO-L-NORLEUCINE | 2022 | Czech Academy of Sciences | 1 |
| NQO1 activated 6-diazo-5-oxo-L-norleucine prodrug and preparation method and application thereof | 2021 | 1 | |
| PHARMACEUTICAL COMPOSITION CONTAINING 6-DIAZO-5-OXO-L-NORLEUCINE FOR TREATMENT OF INFLAMMATORY SKIN DISEASE | 2020 | 1 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 4 |
| 2017 | 6 |
| 2018 | 6 |
| 2019 | 8 |
| 2020 | 3 |
| 2021 | 9 |
| 2022 | 6 |
| 2023 | 8 |
| 2024 | 8 |
| 2025 | 3 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Barbara S. Slusher | Johns Hopkins University | 17 |
| 2 | Jonathan D. Powell | Johns Hopkins University | 6 |
| 3 | Eva Prchalová | Johns Hopkins University | 5 |
| 4 | Yoshimasa Morino | Kumamoto University | 5 |
| 5 | Jesse Alt | Johns Hopkins University | 5 |
| 6 | David A. Cooney | National Cancer Institute | 5 |
| 7 | Joseph Roberts | University of South Carolina | 4 |
| 8 | Kakulavarapu V. Rama Rao | University of Miami | 4 |
| 9 | Philip Newsholme | University College Dublin | 3 |
| 10 | Peter Ekblom | University of Helsinki | 3 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation | 2013 | 604 | Protein Kinase Regulation and GTPase Signaling |
| Functional significance of cumulus expansion in the mouse: Roles for the preovulatory synthesis of hyaluronic acid within the cumulus mass | 1993 | 291 | Sperm and Testicular Function |
| Glutamine and Cancer | 1993 | 290 | Cancer, Hypoxia, and Metabolism |
| Lumen formation by epithelial cell lines in response to collagen overlay: a morphogenetic model in culture. | 1982 | 281 | Cancer Cells and Metastasis |
| We're Not “DON” Yet: Optimal Dosing and Prodrug Delivery of6-Diazo-5-oxo-L-norleucine | 2018 | 255 | Cancer-related Molecular Pathways |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of 6-diazo-5-oxo-L-norleucine?
Which organizations hold the most patents related to this compound?
What patent applications address prodrug formulations of this compound?
Who are the most prolific authors publishing on this compound, and where do they work?
What is the patent trend for this compound in recent years?